Goal Guide · 2026
Best Peptides for Recovery and Healing
Summary
The strongest evidence for recovery and healing points to BPC-157, CJC-1295, and Cerebrolysin. CJC-1295 elevates growth hormone and IGF-1, accelerating tissue repair and improving sleep quality critical to recovery. Cerebrolysin provides neuroprotective and neurotrophic support, showing benefit in stroke and neurological recovery. ACE-031 supports muscle regeneration in wasting conditions. These peptides work through distinct biological pathways, making peptide selection highly dependent on the specific recovery target.
Understanding Recovery and Healing with Peptides
Peptides relevant to recovery and healing generally operate through three core biological mechanisms: stimulating growth hormone and IGF-1 secretion to accelerate tissue synthesis, modulating inflammatory signaling to reduce recovery-limiting inflammation, and activating neurotrophic pathways that support nerve and brain tissue repair. These mechanisms are not mutually exclusive, and some peptides engage multiple pathways simultaneously, which helps explain their broad utility across different recovery contexts including musculoskeletal injury, metabolic stress, and neurological damage.
Growth hormone-releasing peptides and analogs such as CJC-1295 are particularly relevant to physical recovery because growth hormone and IGF-1 are primary drivers of collagen synthesis, muscle protein synthesis, and anabolic repair processes. Separately, neurotrophic peptide preparations like Cerebrolysin address recovery at the neurological level by promoting neuronal survival, synaptic plasticity, and functional restoration following brain injury or stroke. Myostatin inhibitors such as ACE-031 target skeletal muscle specifically, counteracting the catabolic signals that impair muscle regeneration in disease states.
The evidence landscape for recovery-focused peptides is heterogeneous. CJC-1295 holds Grade B evidence based on human clinical data demonstrating sustained GH and IGF-1 elevation, though large randomized controlled trials specifically for injury recovery remain limited. Cerebrolysin carries Grade B evidence supported by multiple controlled trials in stroke and traumatic brain injury populations, with meta-analyses showing statistically significant improvements in neurological outcomes. ACE-031 has shown promising Phase 1 and 2 data in muscular dystrophy but lacks long-term safety data. Researchers continue to refine dosing protocols and patient selection criteria across all categories.
Peptides Ranked by Evidence (77 found)
| Peptide | Evidence | |
|---|---|---|
| Retatrutide | AEvidenceGrade ALarge human randomised controlled trials or FDA/major-authority approved | Research → |
| Semaglutide | AEvidenceGrade ALarge human randomised controlled trials or FDA/major-authority approved | Research → |
| Tesamorelin | AEvidenceGrade ALarge human randomised controlled trials or FDA/major-authority approved | Research → |
| ACE-031 | BEvidenceGrade BSmaller human trials, observational studies, or approved in 30+ countries | Research → |
| CJC-1295 | BEvidenceGrade BSmaller human trials, observational studies, or approved in 30+ countries | Research → |
| Cerebrolysin | BEvidenceGrade BSmaller human trials, observational studies, or approved in 30+ countries | Research → |
| GHK | BEvidenceGrade BSmaller human trials, observational studies, or approved in 30+ countries | Research → |
| GHK-Cu | BEvidenceGrade BSmaller human trials, observational studies, or approved in 30+ countries | Research → |
| Glucagon-Like Peptide-2 (GLP-2) | BEvidenceGrade BSmaller human trials, observational studies, or approved in 30+ countries | Research → |
| Kisspeptin-10 | BEvidenceGrade BSmaller human trials, observational studies, or approved in 30+ countries | Research → |
| N-Acetyl Selank Amidate | BEvidenceGrade BSmaller human trials, observational studies, or approved in 30+ countries | Research → |
| NA-Semax-Amidate | BEvidenceGrade BSmaller human trials, observational studies, or approved in 30+ countries | Research → |
| SS-31 | BEvidenceGrade BSmaller human trials, observational studies, or approved in 30+ countries | Research → |
| Semax | BEvidenceGrade BSmaller human trials, observational studies, or approved in 30+ countries | Research → |
| Sermorelin | BEvidenceGrade BSmaller human trials, observational studies, or approved in 30+ countries | Research → |
| Thymalin | BEvidenceGrade BSmaller human trials, observational studies, or approved in 30+ countries | Research → |
| Alpha-MSH | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| BPC-157 | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| Bronchogen | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| CJC-1293 | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| Cardiogen | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| Cartalax | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| Chonluten | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| Cortagen | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| FGL | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| Follistatin | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| GHRP-1 | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| GHRP-2 | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| GHRP-3 | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| GHRP-4 | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| GHRP-6 | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| IGF-1 DES | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| IGF-1 LR3 | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| Ipamorelin | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| KPV | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| LL-37 | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| Livagen | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| MGF | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| Matrixyl | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| Ovagen | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| PEG-MGF | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| Palmitoyl Tetrapeptide-7 | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| Pancragen | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| Pinealon | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| Prostamax | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| Snap-8 | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| TB-500 | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| Testagen | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| Thymagen | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| Vesilute | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| Vesugen | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| Vilon | CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data | Research → |
| 5-Amino-1MQ | DEvidenceGrade DTheoretical or in-vitro only; no meaningful independent human evidence | Research → |
| AHK-Cu | DEvidenceGrade DTheoretical or in-vitro only; no meaningful independent human evidence | Research → |
| Adamax | DEvidenceGrade DTheoretical or in-vitro only; no meaningful independent human evidence | Research → |
| Adipotide | DEvidenceGrade DTheoretical or in-vitro only; no meaningful independent human evidence | Research → |
| Apelin | Research → | |
| Apigenin | Research → | |
| Collagen Peptide (Hydrolyzed Collagen) | Research → | |
| Diacerein | Research → | |
| FOXO4-DRI | DEvidenceGrade DTheoretical or in-vitro only; no meaningful independent human evidence | Research → |
| Ginseng Peptide (GS-Peptide) | Research → | |
| Humanin | DEvidenceGrade DTheoretical or in-vitro only; no meaningful independent human evidence | Research → |
| Lactoferrin-derived Peptides (LfcinB) | Research → | |
| Leptin | Research → | |
| Metformin | Research → | |
| Myostatin | DEvidenceGrade DTheoretical or in-vitro only; no meaningful independent human evidence | Research → |
| NAD+ | Research → | |
| Pal-AHK | DEvidenceGrade DTheoretical or in-vitro only; no meaningful independent human evidence | Research → |
| Pal-GHK | DEvidenceGrade DTheoretical or in-vitro only; no meaningful independent human evidence | Research → |
| Palmitoyl Dipeptide-6 | DEvidenceGrade DTheoretical or in-vitro only; no meaningful independent human evidence | Research → |
| Pentadecapeptide BPC 157 | Research → | |
| Syn-Coll | DEvidenceGrade DTheoretical or in-vitro only; no meaningful independent human evidence | Research → |
| Teriparatide | Research → | |
| Tripeptide-29 | DEvidenceGrade DTheoretical or in-vitro only; no meaningful independent human evidence | Research → |
| Tripeptide-3 | DEvidenceGrade DTheoretical or in-vitro only; no meaningful independent human evidence | Research → |
| Vialox | DEvidenceGrade DTheoretical or in-vitro only; no meaningful independent human evidence | Research → |
Top Picks by Evidence Grade
Retatrutide
AEvidenceGrade ALarge human randomised controlled trials or FDA/major-authority approvedImproves metabolic health
View research page →
Semaglutide
AEvidenceGrade ALarge human randomised controlled trials or FDA/major-authority approvedMay improve metabolic health markers
View research page →
Tesamorelin
AEvidenceGrade ALarge human randomised controlled trials or FDA/major-authority approvedReduces visceral adipose tissue
View research page →
ACE-031
BEvidenceGrade BSmaller human trials, observational studies, or approved in 30+ countriesImproves muscle regeneration capacity
View research page →
Getting Started
Define Your Recovery Target
Recovery and healing encompasses musculoskeletal repair, neurological recovery, and metabolic restoration, each supported by different peptide classes. Research suggests clearly identifying the tissue system involved before evaluating which peptide mechanism is most applicable.
Review Evidence Grade and Safety Profile
Peptides with higher evidence grades such as Cerebrolysin for neurological recovery or CJC-1295 for anabolic tissue repair have more robust clinical data to reference. Consulting published clinical trial literature helps contextualize both efficacy signals and known adverse effect profiles for each compound.
Consult a Qualified Medical Professional
Research on recovery peptides is conducted under clinical supervision with defined protocols, patient monitoring, and outcome tracking. A licensed physician or specialist familiar with peptide pharmacology is best positioned to evaluate individual suitability based on health status and recovery goals.
Related Side-by-Side Comparisons
Detailed evidence comparisons for the top recovery and healing peptides.
Frequently Asked Questions
How do peptides differ from traditional recovery interventions like NSAIDs or physical therapy?⌄
Are peptides for recovery suitable for both acute injury and chronic conditions?⌄
How long does recovery with peptide protocols typically take in research settings?⌄
Can multiple recovery peptides be combined in research protocols?⌄
Not sure where to start?
The Goal Finder asks 3 questions and gives you a personalised peptide recommendation ranked by evidence grade.